Two posters presented at the CHEST Annual Meeting 2023 showed how real-world exacerbation rates in asthma and chronic obstructive pulmonary disease (COPD) dropped after patients started using a single ...
Mepolizumab significantly reduces exacerbations in patients with asthma and concurrent chronic obstructive pulmonary disease (COPD), with a 55% reduction in COPD exacerbations post initiation. A ...
Please provide your email address to receive an email when new articles are posted on . Patients using cyclobenzaprine or methocarbamol had increased relative risk for COPD exacerbations, researchers ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Hospitalization duration for a COPD exacerbation was ...
In some patients with chronic obstructive pulmonary disease (COPD), type 2 inflammation may increase exacerbation risk and may be indicated by elevated blood eosinophil counts. Dupilumab, a fully ...
Dupilumab significantly reduced exacerbations in adults with chronic obstructive pulmonary disease by approximately 30% compared with placebo, based on data from approximately 900 individuals. Chronic ...
Clinical guidelines recommend use of exacerbation history in choosing therapies to predict the risk for chronic obstructive pulmonary disease exacerbations, but an analysis of data from three ...
Credit: Scott Bodell/MedicalImages.com The authors outline preventative pharmacologic therapies for COPD exacerbations and a patient-tailored approach to management. Chronic obstructive pulmonary ...
In conjunction with World Chronic Obstructive Pulmonary Disease (COPD) Day, organised by the World Health Organisation and the Global Initiative for Chronic Obstructive Lung Disease (GOLD), a research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results